To explore the clinical perspectives and treatment strategies for adverse cutaneous reactions associated with medications, particularly focusing on targeted therapies, immunotherapies, and their specific mechanisms.
Key Findings:
Dupilumab was effective in treating ICI-induced bullous pemphigoid, demonstrating its potential in managing severe cutaneous reactions.
SCORTEN parameters may need recalibration for better mortality risk stratification in SJS/TEN, suggesting a need for updated clinical guidelines.
JAK inhibitors are associated with increased infection risks, including herpetic infections, highlighting the importance of monitoring.
Topical steroids can lead to significant adverse effects, including iatrogenic Cushing syndrome, necessitating careful patient management.
Multidisciplinary management is crucial for complex cutaneous reactions in oncological patients, underscoring the need for collaborative care.
Interpretation:
The findings highlight the evolving landscape of cutaneous adverse events due to targeted therapies and immunotherapies, necessitating a comprehensive understanding of their mechanisms and management strategies to improve patient outcomes.
Limitations:
Real-world data on infection risks associated with JAK inhibitors are still lacking, which may limit the applicability of findings.
Potential biases in retrospective analyses, such as selection bias and confounding factors, may affect the reliability of findings.
Limited generalizability of case studies due to small sample sizes, which may not represent broader patient populations.
Conclusion:
The shift towards targeted therapies and immunotherapies has introduced complex challenges in managing cutaneous adverse events, emphasizing the need for specialized, multidisciplinary approaches, active pharmacovigilance, and ongoing research to adapt to these evolving therapies.
